Suggestions
Liam Killingstad
Working to make the world a better place for patients
Liam Killingstad, an accomplished professional with a diverse background in finance and healthcare, is making significant contributions in his role as Chief of Staff at SHEPHERD Therapeutics. With experience in financial services, data analytics, and research product development, Killingstad brings a unique skill set to drive the company's strategic vision and execution.
Before joining SHEPHERD, Killingstad served as an Operating Partner at a private family office, where he honed his expertise in financial management and operations. Prior to that, he held the position of Senior Vice President of Business Development and Operations at SHEPHERD, where he played a pivotal role in expanding the company's reach and impact.
Killingstad's impressive academic background includes a dual degree in Accounting and Finance, as well as Economics, from Case Western Reserve University. His academic achievements earned him the prestigious Nellie Chittenden Carlton Prize for outstanding work in economics. Furthermore, his athletic prowess was recognized as a three-time UAA All Academic Team member during his time at Case Western.
Passionate about leveraging his analytical skills and economic insights to create better outcomes for patients and healthcare stakeholders, Killingstad is dedicated to the mission of SHEPHERD Therapeutics. As the Chief of Staff, he oversees crucial areas such as business development, operations, and communications, while managing various cross-functional projects and initiatives.
In addition to his professional endeavors, Killingstad has been involved with organizations such as Front Office Sports and has gained valuable experience as an Investment Banking Associate at globally renowned firm Goldman Sachs.
Overall, Liam Killingstad's expertise in finance, data analytics, and strategic development, combined with his drive to make a difference in the healthcare industry, make him a valuable asset in his role as Chief of Staff at SHEPHERD Therapeutics.